Previous 10 | Next 10 |
Gainers: Cellect Biotechnology APOP +43%, ProQR Therapeutics (PRQR) +33%, Immutep Limited (IMMP) +29%, F-star Therapeutics (FSTX) +24%, Cancer Genetics CGIX +13%.Losers: Evolus EOLS -24%, Rite Aid RAD -24%, Evofem Biosciences (EVFM) ...
Bristol Myers Squibb ([[BMY]] -0.2%) trades marginally lower in the morning hours despite the pre-market announcement of the positive results from relatlimab and Opdivo combo in a Phase 2/3 trial in previously untreated metastatic or unresectable melanoma.Relatlimab is an anti-LAG-3 anti...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced...
F-star Therapeutics (FSTX) jumps 16% premarket after Merck KGaA (MKGAF) reports 5.4% passive stake in the company.Press Release For further details see: Merck KGaA discloses 5.4% stake in F-star Therapeutics
F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...
The European Patent Office ((EPO)) has granted F-star Therapeutics (FSTX) a patent with claims protecting the composition of matter of company's FS118 molecule throughout Europe.The expiry date of the patent is expected to be June 2037. The decision to grant this patent follows the EPO’...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces...
FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company’s third bispecific to enter clinical trials Preclinical studies demonstrated potent clustering and activation of CD137 by FS222 that is conditional on PD-L...
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can...